Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Surprised by targeted degrader’s single dose potency, Kymera broadens thinking on discovery platform

Company considering shorter term and more infrequent dosing for earlier stage programs

By Karen Tkach Tuzman, SEnior Editor
June 29, 2021 12:29 AM UTC

Beating expectations for its first clinical targeted degrader is pushing Kymera to consider lower dosing for its lead inflammation program, and broader use cases for its next generation of products.

Kymera Therapeutics Inc. (NASDAQ:KYMR) announced Monday that lead compound KT-474 induced a median of 90% IRAK4 degradation in the 300 mg cohort of its randomized, controlled Phase I study in healthy volunteers; based on preclinical studies, the company was shooting for 85%. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Kymera Therapeutics Inc.